Strategic capabilities Proteome Sciences provides contract proteomics services with proprietary workflows (SysQuant, TMTMS2, Super-Depletion, TMTcalibrator) and targeted MS-based biomarker assays, offering opportunities to partner for drug discovery, biomarker discovery, and validation across neurodegenerative diseases, cancer, and stroke.

Capacity expansion Recent financing to acquire an Exploris mass spectrometer indicates capacity growth and enhanced order fulfillment potential, suggesting sales opportunities in expanding collaborations, larger project engagements, and faster turnaround for pharma/diagnostics clients.

Global reach State-of-the-art facility in Frankfurt certified to ISO 9001:2015 and GCLP supports high-quality, regulated proteomics services, enabling collaborative partnerships with multinational pharma companies seeking compliant outsourcing partners.

Market expansion Recent launch of SysQuant SCP for single-cell proteomics and early-stage market activities in biomarker discovery position the company to offer cutting-edge services to customers pursuing single-cell insights and novel biomarker programs.

Evidence of demand Revenue scale ($1–10M) and a track record of biomarker discovery across diverse sample types imply active interest from pharma and diagnostics segments; potential sales emphasis on expanding service breadth, custom assay development, and biomarker validation workflows.